Used in oncology research as a dual inhibitor targeting PI3K and mTOR pathways, showing potential in suppressing tumor growth in various cancer models. Demonstrates activity against solid tumors by blocking signaling involved in cell proliferation and survival. Investigated for its efficacy in breast, prostate, and lung cancer studies, particularly in PTEN-deficient or PI3K-mutated cell lines. Also utilized in combination therapies to overcome resistance to conventional treatments. Exhibits blood-brain barrier penetration, supporting exploration in brain tumor research.